Company Description
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex.
Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Scott Braunstein |
Contact Details
Address: 5 Radnor Corporate Center, Suite 500 Radnor, Pennsylvania 19087 United States | |
| Phone | 484 801 4670 |
| Website | marinuspharma.com |
Stock Details
| Ticker Symbol | MRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267813 |
| CUSIP Number | 56854Q200 |
| ISIN Number | US56854Q2003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott N. Braunstein M.D. | Chief Executive Officer, President and Chairman |
| Steven E. Pfanstiel C.M.A., M.B.A. | Chief Operating Officer, Chief Financial Officer and Treasurer |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Dr. Alex Aimetti Ph.D. | Chief Scientific Officer |
| Sonya Weigle | Senior Vice President of Investor Relations, Human Resources and Corporate Affairs |
| Martha E. Manning Esq., J. D. | Senior Vice President, General Counsel and Secretary |
| Molly Cameron | Director of Corporate Communications and Investor Relations |
| Dr. Kimberly A. McCormick Pharm.D. | Chief Regulatory and Quality Assurance Officer |
| Christina Shafer | Chief Commercial Officer |
| David Czekai | Chief Chemistry, Manufacturing and Controls Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |